Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study evaluating NXP900 in combination with EGFR and ALK inhibitors in patients with advanced non-small cell lung cancer

Next Previous
Trial Profile

Study evaluating NXP900 in combination with EGFR and ALK inhibitors in patients with advanced non-small cell lung cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NXP 900 (Primary) ; Anaplastic lymphoma kinase inhibitors; Epidermal growth factor receptor modulators
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 23 Oct 2024 According to Nuvectis Pharma Media release, data from this study will be presented at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics on October 24th, 2024.
  • 08 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top